Konu "K562" için listeleme
Toplam kayıt 2, listelenen: 1-2
-
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells
(Taylor & Francis LTD, 2016)Inhibition of the proteasome has emerged as a clinically effective anticancer therapeutic approach in recent years. Bortezomib (Velcade (R)) showed extremely high potency against a wide range of cancer cell lines. Ixazomib ... -
Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells
(Lippincott Williams & Wilkins, 2019)Neurokinin-1 receptor (NK1R) antagonists are known for their anxiolytic, antiemetic, anticancer, and antiinflammatory effects. Aprepitant is used in vomiting and nausea, which are the most common side-effects of patients ...